Dexcom Inc
NASDAQ:DXCM

Watchlist Manager
Dexcom Inc Logo
Dexcom Inc
NASDAQ:DXCM
Watchlist
Price: 80.23 USD 0.06% Market Closed
Market Cap: 31.3B USD
Have any thoughts about
Dexcom Inc?
Write Note

Dexcom Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dexcom Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Dexcom Inc
NASDAQ:DXCM
Long-Term Debt
$2.5B
CAGR 3-Years
12%
CAGR 5-Years
19%
CAGR 10-Years
97%
Becton Dickinson and Co
NYSE:BDX
Long-Term Debt
$17.9B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
17%
Boston Scientific Corp
NYSE:BSX
Long-Term Debt
$9.2B
CAGR 3-Years
2%
CAGR 5-Years
-1%
CAGR 10-Years
8%
Stryker Corp
NYSE:SYK
Long-Term Debt
$13.3B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
15%
Abbott Laboratories
NYSE:ABT
Long-Term Debt
$12.8B
CAGR 3-Years
-10%
CAGR 5-Years
-6%
CAGR 10-Years
13%
Intuitive Surgical Inc
NASDAQ:ISRG
Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Dexcom Inc
Glance View

Market Cap
31.3B USD
Industry
Health Care
Economic Moat
Narrow

Dexcom Inc. emerged as a pioneering force in the realm of continuous glucose monitoring (CGM), redefining the landscape of diabetes management. Founded in 1999, this San Diego-based company disrupted traditional blood glucose monitoring with its innovative technology, allowing individuals to track glucose levels in real-time without frequent finger-pricking. The company’s CGM systems, such as the G6 model, utilize a small sensor inserted beneath the skin that transmits data to a wearable device or smartphone, allowing patients and healthcare providers a comprehensive view of glucose trends. This approach empowers users with critical information for better diabetes management, reducing the likelihood of complications resulting from high or low blood sugar. Dexcom’s revenue generation revolves around the sales of its CGM systems, sensors, and related software services. By selling the initial monitoring devices and disposable sensors that typically need to be replaced every ten days, the company ensures a steady, recurring revenue stream. Furthermore, its integration with healthcare providers and insurers broadens its reach, tapping into a vast network of patients worldwide. Dexcom also collaborates with tech giants to enhance interoperability and data analytics, thereby embedding its solutions in broader digital health ecosystems. As diabetes continues to be a growing global concern, Dexcom’s strategic focus on innovation and strategic partnerships positions it as a leader in the CGM market.

DXCM Intrinsic Value
44.01 USD
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Dexcom Inc's Long-Term Debt?
Long-Term Debt
2.5B USD

Based on the financial report for Sep 30, 2024, Dexcom Inc's Long-Term Debt amounts to 2.5B USD.

What is Dexcom Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
97%

Over the last year, the Long-Term Debt growth was 0%. The average annual Long-Term Debt growth rates for Dexcom Inc have been 12% over the past three years , 19% over the past five years , and 97% over the past ten years .

Back to Top